HER2-Positive

Article

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in HER2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–HER2 Therapy

March 30, 2023

When every data point represents a patient, accuracy and integrity aren’t optional — they’re everything. That’s why it’s IDDI.

Start Now